NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis

Xenon Pharmaceuticals Inc. (XENE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

XENE

$35.95

−$0.32 (−0.88%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XENE with… →

XENE Key Statistics

As of Oct 21, 2026
Trading
Open
$36.55
Previous Close
$36.27
Day's Range
35.89–37.00
52-Week Range
33.38–72.66
Volume
1.08M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$3.48B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.74
Financials (FY)
Revenue (FY)
$7.50M
Net Income (FY)
−$345.91M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
96.84M
1-Year Return
−16.47%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
1.43M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, XENE closed at $35.95, −16.47% over 1 year.

Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $3.48B.

In fiscal 2025, XENE reported revenue of $7.50M.

XENE Stock Return by Calendar Year

Xenon Pharmaceuticals Inc. (XENE) 10-year return: what $10,000 became

1 year
$10,000 $8,353
−16.47%
5 years
$10,000 $11,737
+17.37%
10 years
$10,000 $42,047
+320.47%

If you had invested $10,000 in Xenon Pharmaceuticals Inc. (XENE) 10 years ago, at the close on October 21, 2016, it would have been worth $42,047 at the close on October 21, 2026: +320.47% in total, +15.44% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−19.79%
2025+14.34%
2024−14.89%
2023+16.81%
2022+26.22%
2021+103.12%
2020+17.32%
2019+107.77%
2018+123.36%
2017−63.31%
2016 (partial year)+1.85%

As of October 21, 2026.

XENE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.50M−$345.91M−4,612.1%
2024$0.00−$234.33M—
2023$0.00−$182.39M—
2022$9.43M−$125.37M−1,328.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.50M—−$373.07M−$345.91M−4,612.1%
2024$0.00—−$279.30M−$234.33M—
2023$0.00—−$214.05M−$182.39M—
2022$9.43M—−$129.14M−$125.37M−1,328.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Xenon Pharmaceuticals Inc. (XENE) carries a market capitalisation of $3.48B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 358 employees.

XENE last closed at $35.95 on October 21, 2026. That is −$0.32 (−0.88%) against the previous close. The 52-week range on file runs from $33.38 to $72.66. The latest close sits 7.7% above that 52-week low.

Financial Health

In fiscal 2025, Xenon Pharmaceuticals Inc. reported revenue of $7.50M. The same year closed with a net loss of $345.91M. Earnings per share on a trailing basis come to −4.74.

Across the 4 fiscal years on file, revenue moves from $9.43M in 2022 to $7.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.6. Annualized volatility over the trailing 10 years is 67.03%. Over the trailing twelve months the total return is −16.47%. Across 10 years the annualized return works out at +15.44%.

Growth & Income

No dividend is on file for XENE.

2026 is still running; the total return is −19.79% year to date. The strongest complete calendar year on file is 2018 at +123.36%; the weakest is 2017 at −63.31%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Xenon Pharmaceuticals Inc. (XENE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xenon Pharmaceuticals Inc. XENE $3.48B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Xenon Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Visit website →